Low-Dose Rapamycin.

Leucine signals through Sestrin2 and the Rag GTPases to switch mTORC1 on, which is the exact complex rapamycin restrains. Timing them together works against the intended direction of each.

Whey delivers a large, fast leucine load that is the strongest dietary activator of mTORC1. Formulators separate a protein bolus from a rapamycin dose because the two pull the same switch in opposite directions.

Essential amino acids, leucine in particular, are the amino acid input that permits mTORC1 activation at the lysosome. That input runs counter to mTOR restraint.

HMB is a leucine metabolite that signals through the same mTORC1 axis to raise protein synthesis. Its purpose is the opposite of what an mTOR inhibitor is doing.

Metformin raises the AMP to ATP ratio and activates AMPK, which restrains mTORC1 through TSC2 and raptor. It reaches the same node rapamycin binds, from upstream.

Berberine activates AMPK, converging on the same mTORC1 restraint, and it also inhibits CYP3A4 and P-glycoprotein, the enzyme and transporter that clear rapamycin. The second effect can raise circulating levels well beyond what the dose suggests.

Spermidine induces autophagy largely through EP300 acetyltransferase inhibition rather than mTOR. It reaches a similar cellular endpoint by a separate route.

Resveratrol activates AMPK and sirtuin signalling, which sits upstream of mTORC1 restraint. The overlap is at the network level rather than a shared binding site.

Hyperforin strongly induces CYP3A4 and P-glycoprotein, the pair that clears rapamycin from the body. Co-use markedly lowers rapamycin exposure and is one of the better documented herb interactions on record.

Piperine inhibits both CYP3A4 and P-glycoprotein, the main clearance route for rapamycin. That raises exposure from an unchanged dose, which matters for a narrow-window compound.

Quercetin inhibits CYP3A4 and P-glycoprotein at intakes reached by concentrated extracts. The result is a higher rapamycin level than the label dose implies.

Silymarin flavonolignans modestly inhibit CYP3A4 and several drug transporters. The size of the shift is smaller than with piperine but sits on the same clearance route.

Arginine is sensed in the lysosomal lumen through SLC38A9 and CASTOR1, and that sensing recruits mTORC1 to the lysosome where it can be activated. Rapamycin acts downstream by way of FKBP12, so arginine loading pushes the pathway rapamycin restrains. Anyone taking both should understand they oppose each other at the same node, whichever direction they want.

Glutamine feeds mTORC1 activation both through glutaminolysis to alpha-ketoglutarate and through Rag-independent lysosomal recruitment. High-dose glutamine therefore raises the tone of the pathway rapamycin damps. The opposition is well described in cell biology; nobody has quantified it in people taking a supplement alongside the drug.

S-adenosylmethionine, the immediate product of methionine, binds SAMTOR and releases its restraint on mTORC1, which is why methionine restriction shows up repeatedly in the same experimental literature as mTOR inhibition. Supplemental methionine moves this in the opposite direction. This is established nutrient sensing, not a tested human interaction.

Valine sits with leucine and isoleucine among the branched-chain amino acids that drive mTORC1-dependent translation. A 2026 cell study in bovine mammary cells examined valine, lysine and threonine combinations for casein synthesis, a non-human system where the same pathway carries the signal. Direction of opposition is clear; magnitude in a person is not.

Any leucine-rich protein bolus activates AKT and mTORC1 signalling toward muscle protein synthesis, and a 2025 study of protein supplementation with exercise traced exactly that pathway. Casein delivers the same amino acids as whey on a slower release curve, so the activation is lower and longer. It still opposes an mTOR inhibitor rather than complementing it.

Creatine's main action is phosphocreatine buffering of ATP, which is independent of mTOR. Part of its effect on muscle size in training studies has been attributed to raised mTOR pathway signalling, and that portion runs into an mTOR inhibitor. The overlap is partial and the interaction has not been measured in people.

Rapamycin is a CYP3A4 substrate with substantial P-glycoprotein handling, and curcuminoids inhibit both in vitro and in some human pharmacokinetic work. Adding curcumin can therefore raise rapamycin exposure without any change in dose. Concentration changes in a narrow-index drug are a prescriber's business, and the interaction direction is what matters here.

EGCG suppresses PI3K/AKT/mTOR signalling in a range of cell models, which points the same direction as rapamycin, and it also interacts with efflux transporters that handle the drug. The signalling work is in vitro at concentrations oral dosing does not reach. Both the additive pathway effect and the transporter effect are worth flagging rather than relying on.

Glycyrrhizin and its metabolites alter CYP3A activity and inhibit 11-beta-hydroxysteroid dehydrogenase type 2, which raises blood pressure and lowers potassium at sustained intakes. Both matter next to a CYP3A4 substrate that itself affects electrolyte and blood pressure handling. The direction of the enzyme effect in humans is inconsistent across studies.

NAD precursors raise substrate availability for sirtuins and support AMPK-linked signalling, both of which sit in the same nutrient-sensing network as mTORC1 without acting on it directly. This is why the two appear together in longevity-research discussion. There is no combination study, and the pathway map does not tell you what a pairing does in a person.

Alpha-lipoic acid influences AMPK activity in several tissue models, and AMPK activation restrains mTORC1 through TSC2 and raptor phosphorylation. That points the same way as rapamycin. The lipoic acid data are largely preclinical and its AMPK effects are tissue-dependent, including reports in opposite directions.

Caffeine inhibits mTOR signalling in cell models at millimolar concentrations, well above what a normal dose produces in blood, and it independently promotes autophagy markers in animal work. The overlap with rapamycin is therefore theoretical at dietary intakes. Included so the direction is on record, not as a reason to combine them.

Monacolin K in red yeast rice is chemically lovastatin and is cleared by CYP3A4, the same enzyme that handles rapamycin, so co-use puts two substrates on one route. Rapamycin is also recognised to raise circulating lipid markers, which is the marker red yeast rice is taken to lower. Two opposing pressures on the same marker plus shared clearance is worth stating plainly.